Condition: NSCLC · Locally Advanced · Sponsor: Montefiore Medical Center
Determine anti-tumor efficacy by characterizing response rates on positron emission tomography (PET) following three cycles of induction immunotherapy with cemiplimab and fianlimab without chemotherapy for locally advanced non-small cell lung cancer (LA-NSCLC).
This description comes directly from the study's public registry record.
Nitin Ohri, MD, MS · 718-405-8550 · nitin.ohri@einsteinmed.edu
Always discuss trial participation with your own doctor first.
| Montefiore Einstein Comprehensive Cancer Center (MECCC) | The Bronx, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06865339